Surrozen Inc Earnings
The next earnings date for Surrozen Inc has not yet been scheduled.
Analyst Estimates of Surrozen Inc Earnings
| No results. | |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Surrozen Inc Earnings: Historical
| 11/09/2026 | After Market | $-4.75 | -259.85% |
| 08/14/2026 | --- | $-0.41 | 69.40% |
| 05/06/2026 | After Market | $-4.63 | -543.06% |
| 03/24/2026 | --- | $-9.62 | -678.79% |
| 11/07/2025 | After Market | $-3.60 | -207.69% |
| 08/08/2025 | After Market | $-1.14 | 7.32% |
| 05/09/2025 | After Market | $7.92 | 826.61% |
| 03/31/2025 | --- | $-9.09 | -236.67% |
| 11/06/2024 | Before Market | $-0.44 | 84.12% |
| 08/12/2024 | After Market | $-7.99 | -186.38% |
More About Surrozen Inc
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
“Surrozen Inc Earnings” Can Refer to the Surrozen Inc Earnings Date
Some people say “Surrozen Inc earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Surrozen Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Surrozen Inc Stock on the Earnings Date
If you own Surrozen Inc stock (SRZN) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Surrozen Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Surrozen Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More Surrozen Inc Earnings
You can contact us any time if you would like to ask questions about Surrozen Inc earnings or anything else related to the stock market.